Synopsis: A Small-cap Firm that gives diagnostic companies is in focus in the present day after asserting robust Q2 outcomes.
India’s main client healthcare model in diagnostic companies, is within the highlight in the present day after posting Q2FY26 outcomes. Learn the article beneath for detailed insights into its efficiency.
With a market capitalization of Rs. 26,255.24 crore, the shares of Dr Lal Pathlabs Restricted is buying and selling at Rs. 3,135, up by 1.48 % from its earlier closing value of Rs. 3,089.40. The inventory has touched an intraday excessive of Rs. 3,208.90 in in the present day’s buying and selling session.
Bonus Problem
Dr Lal Pathlabs Restricted has introduced a document date for the 1:1 bonus share subject, giving one new totally paid-up fairness share of Rs. 10 for every current share. The corporate will announce the document date for figuring out shareholders’ eligibility to obtain bonus fairness shares at a later time.
Q2FY26 Outcomes & Dividend Bulletins
Dr Lal Pathlabs Restricted reported Rs. 730.6 crore in income for the second quarter of FY26, an 10.66 % improve over the Rs. 660.2 crore for a similar interval in FY25. It elevated by 9.08 % as in comparison with Rs. 669.8 crore in Q1 FY26.
The corporate’s EBITDA for Q2 FY26 stood at Rs. 224.1 crore, up by 16.54 % from Rs. 192.3 crore in Q1 FY26, and inclined by 10.66 % from Rs. 202.5 crore in Q2 FY25.
The consolidated web revenue for the second quarter of FY26 was Rs. 152.2 crore, which was 14.35 % greater than the Rs. 133.1 crore reported within the earlier quarter and elevated by 17.08 % from Rs. 130 crore in Q2 FY25. Revenue progress was additionally mirrored in earnings per share (EPS), which elevated to roughly Rs. 18.05 in Q2 FY26 from Rs. 15.52 in Q2 FY25.
The corporate has introduced an 2nd interim dividend of Rs. 7 per fairness share (70 % of face worth of Rs. 10), with November 7, 2025, designated because the document date to find out eligible shareholders.
In regards to the firm
Dr. Lal PathLabs is a number one diagnostic service supplier in India, providing a variety of checks for analysis, prevention, and therapy via a nationwide community. As of March 31, 2025, it operates 298 laboratories, 6,607 affected person service facilities, and 12,365 pickup factors, serving people, hospitals, and firms.
A return on fairness (ROE) of about 24.3 %, a return on capital employed (ROCE) of about 28.9 % and debt to fairness ratio of 0.07 exhibit the corporate’s monetary place. In the meanwhile, the corporate’s P/E ratio is 51x greater as in comparison with its trade P/E 37.4x.
As of September 2025, the corporate’s shareholding sample reveals that promoters maintain 53.21 % of the whole fairness, indicating robust promoter possession. International Institutional Traders (FIIs) maintain 21.86 %, whereas Home Institutional Traders (DIIs) personal 18.22 %. The federal government holds 0.27 %, public shareholding stands at 6.07 %, and 0.37 % by others.
Written By Akshay Sanghavi
Disclaimer
The views and funding ideas expressed by funding specialists/broking homes/ranking businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of economic losses. Traders should due to this fact train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Non-public Restricted or the writer usually are not chargeable for any losses brought on on account of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
